Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$572M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$495M |
| 3 |
iShares MBS ETF
MBB
|
+$405M |
| 4 |
Procter & Gamble
PG
|
+$365M |
| 5 |
Microsoft
MSFT
|
+$327M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$605M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$544M |
| 3 |
Sempra
SRE
|
+$474M |
| 4 |
CELG
Celgene Corp
CELG
|
+$411M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$380M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.85% |
| 2 | Healthcare | 5.77% |
| 3 | Financials | 5.26% |
| 4 | Consumer Discretionary | 4.71% |
| 5 | Communication Services | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3951
PUT
Synchrony
SYF
$25.8B
| $691K | ﹤0.01% |
19,200
+1,100
| +6% | +$39.4K |
|
3952
CALL
Box
BOX
$4.43B
| $690K | ﹤0.01% |
41,100
-16,800
| -29% | -$282K |
|
|
CERN
3953
CALL
DELISTED
Cerner Corp
CERN
| $690K | ﹤0.01% |
9,400
-4,300
| -31% | -$297K |
|
3954
BioCryst Pharmaceuticals
BCRX
$2.31B
| $688K | ﹤0.01% |
199,404
-33,802
| -14% | -$85K |
|
3955
Opko Health
OPK
$1.01B
| $688K | ﹤0.01% |
467,559
+168,906
| +57% | +$283K |
|
|
NS
3956
DELISTED
NuStar Energy L.P.
NS
| $687K | ﹤0.01% |
26,557
+8,183
| +45% | +$228K |
|
3957
CALL
Encompass Health
EHC
$11B
| $686K | ﹤0.01% |
12,444
+9,679
| +350% | +$525K |
|
|
FSB
3958
DELISTED
Franklin Financial Network, Inc.
FSB
| $686K | ﹤0.01% |
19,966
+6,915
| +53% | +$228K |
|
|
HTT
3959
High Templar Tech Ltd
HTT
$398M
| $685K | ﹤0.01% |
145,426
-675,213
| -82% | -$3.97M |
|
3960
PUT
Icahn Enterprises
IEP
$5.01B
| $683K | ﹤0.01% |
11,100
+9,700
| +693% | +$627K |
|
3961
CALL
Ashland
ASH
$3.28B
| $681K | ﹤0.01% |
8,900
-2,500
| -22% | -$190K |
|
|
FFWM
3962
DELISTED
First Foundation Inc
FFWM
| $680K | ﹤0.01% |
39,106
+19,792
| +102% | +$319K |
|
3963
Quince Therapeutics
QNCX
$28.2M
| $680K | ﹤0.01% |
61
+53
| +663% | +$320K |
|
|
MMP
3964
PUT
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $679K | ﹤0.01% |
10,800
+2,500
| +30% | +$156K |
|
3965
Amneal Pharmaceuticals
AMRX
$5.89B
| $676K | ﹤0.01% |
140,144
+72,051
| +106% | +$250K |
|
|
FITB
3966
PUT
Fifth Third Bancorp
FITB
$52.2B
| $676K | ﹤0.01% |
22,000
-4,900
| -18% | -$144K |
|
3967
National Presto Industries
NPK
$1B
| $676K | ﹤0.01% |
7,642
+489
| +7% | +$42.6K |
|
|
HAYN
3968
DELISTED
Haynes International, Inc.
HAYN
| $676K | ﹤0.01% |
18,892
+6,453
| +52% | +$233K |
|
|
NWLI
3969
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $676K | ﹤0.01% |
2,325
+1,162
| +100% | +$311K |
|
3970
PC Connection
CNXN
$2.17B
| $674K | ﹤0.01% |
13,577
+5,787
| +74% | +$268K |
|
3971
Evolent Health
EVH
$346M
| $674K | ﹤0.01% |
74,576
-46,400
| -38% | -$377K |
|
3972
FB Financial Corp
FBK
$3.09B
| $674K | ﹤0.01% |
17,019
+8,272
| +95% | +$317K |
|
3973
PUT
Copart
CPRT
$26.8B
| $673K | ﹤0.01% |
29,600
+29,200
| +7,300% | +$623K |
|
3974
PUT
Coherent
COHR
$64.2B
| $672K | ﹤0.01% |
19,968
+1,434
| +8% | +$45.7K |
|
3975
Hawkins
HWKN
$2.82B
| $672K | ﹤0.01% |
29,296
+10,060
| +52% | +$213K |
|
Similar funds
Barclays's Q4 2019 Portfolio in Review
As of Q4 2019, Barclays held 7,254 positions worth $180B, up 13% from $160B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Barclays deployed $6.1B of net new capital in Q4 2019, opening 260 new positions and adding to 3,541 existing holdings. Its largest new stake was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
By sector, the portfolio is most concentrated in Technology at 8.9% of assets, up from 7.7% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $605M trimmed.
- Barclays's largest Q4 2019 buy was Pacer iPath Gold ETNs: 1,000,000 shares worth $25.3M.
- Barclays added most to Apple in Q4 2019, an estimated $572M increase.
- Barclays's biggest Q4 2019 reduction was Invesco QQQ Trust, cutting an estimated $605M.
- Barclays fully exited Celgene Corp in Q4 2019, selling an estimated $411M.
- Barclays's ten largest holdings make up 26% of its $180B portfolio in Q4 2019.
- Barclays opened 260 new positions and closed 700 in Q4 2019.
- Barclays's portfolio value rose 13% quarter-over-quarter to $180B.
Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.